Fate Therapeutics gets $15 million CIRM grant for lupus nephritis CAR T trialSep 28Clinical readoutFate TherapeuticsFT819
Fate Therapeutics doses first lupus nephritis patient in Phase 2 FT819 trial, clears FT839 INDAug 13Quarterly updateFate TherapeuticsFT819
Sign inSign in